Repligen Corp

Repligen Corp’s Q4 2025 results show 18% revenue lift to $198 M and 14% organic growth, while 2026 guidance forecasts $810‑$840 M revenue and margin expansion.

Repligen Corporation’s recent financial developments and strategic partnerships highlight its growth prospects, but a cautious stock outlook and mixed market reactions suggest ongoing challenges in the biotechnology sector.

Repligen Corporation is a bioprocessing innovator dedicated to advancing the production of biological drugs, with a stock price of $121.74 as of July 24, 2025.

Repligen Corporation’s financial performance and strategic growth initiatives in 2025 demonstrate its resilience and adaptability in the biotechnology sector, positioning it for long-term success.